As we enter the second half of 2024, we are more steadfast than ever in our commitment to delivering innovative therapies for liver disease patients. Last month, we initiated our second Phase 3 clinical trial in #MASH in our ENLIGHTEN program. These two clinical trials, along with our ongoing Phase 3 trial in #SHTG, will evaluate the safety and efficacy of our investigational #FGF21 analog and bring us one step closer to delivering this potential best-in-class therapy to patients. Learn more about the recent advancements we’ve made in our clinical development pipeline: https://lnkd.in/guaY8Zz #MASH #Innovation #SHTG
89bio’s Post
More Relevant Posts
-
Today we announced topline results from our Phase 1 dose escalation trial in recurrent #GBM, where historical PFS ranges from 2-4 months. BDTX-1535 demonstrated promising clinical activity and more than 1/3 of patients remained on therapy greater than 4 months. These results in heavily pretreated patients are an important first step in understanding the potential of BDTX-1535 to benefit newly-diagnosed GBM patients. We anticipate results from a "window of opportunity" clinical trial of BDTX-1535 in second-line patients with high-grade glioma in 2Q 2024. Read more: https://lnkd.in/eU7hFh8F
To view or add a comment, sign in
-
-
At EE, we believe that people with #cysticfibrosis deserve to be informed of all research and clinical trial opportunities so they are equipped to make the best decisions for themselves. This is the driving force behind our patient registry and our ongoing work to connect potentially eligible individuals with #CF to relevant clinical trials. If you or your child does not benefit from CFTR modulators, sign up to join our registry and get the latest updates on relevant CF clinical trials – sent directly to your inbox! Join EE’s Patient Registry >>> https://bit.ly/3ThVfm7 #CysticFibrosisAwareness #CFResearch #RareDisease #ClinicalTrials #PatientRegistry
To view or add a comment, sign in
-
We celebrate Clinical Trials Day on May 20, marking the start of the first randomized clinical trial by James Lind in 1747. Since then, clinical trials have evolved significantly. Today, they are essential in developing treatments for conditions like myeloma. We thank everyone involved in myeloma clinical trials, from researchers to participants, for their crucial role in advancing safe and effective treatments. #ClinicalTrialsDay #canadianmyelomaresearchgroup #MedicalAdvancements #ResearchHeroes #DrugDevelopment #HealthcareInnovation #PatientAdvocacy #ScienceProgress #ClinicalResearch
To view or add a comment, sign in
-
-
According to Bain & Company, physician experience plays a critical role in clinical trial enrollment – in a recent report, data show that investigators who have a superior experience with trial sponsors enroll twice as many patients. OcuTerra is grateful to maintain strong relationships with investigators across the country who have supported our ongoing Phase 2 DR:EAM clinical trial of OTT166. In fact, Principal Investigator Carl Regillo, MD, has stated that the DR:EAM clinical trial “has been an incredibly smooth study” and “probably the easiest study I’ve ever enrolled”! Learn more about the DR:EAM study and how OTT166 could make a tremendous impact for patients with diabetic retinopathy: https://bit.ly/43SEQbO
Our Dream — OcuTerra
ocuterratx.com
To view or add a comment, sign in
-
Patients are a Virtue! Thanks to John Emmerson (one of our CCC board members) from London Agency and Sara McLaughlin-Barrett from MedWise Consulting for hosting this insightful webinar on 'Clinical Trials and Tribulations'. Some key insights and quotes: "How is it that we are doing something to a patient and the patient isn't involved? We need to remember that clinical trials are about knowledge exchange and patients are the experts." Libby Noble Alexion Pharmaceuticals, Inc. "Patient organisations play an important role in helping to share information about clinical trials." Cathy Slattery Rare Cancers Australia "Sometimes patients perceive clinical trials as negative and that they are 'guinea pigs'. This could not be further from the truth." A/Prof Tom John Peter MacCallum Cancer Centre "Patients have so many questions like; where do I find out what clinical trials are available? Am I eligible? How much does it cost? Will I be on placebo? Will I have a multidisciplinary team? What is a clinical trial?" DAVID YOUNG The complete webinar is now live, and you can watch it here. https://lnkd.in/ganG6nYG Feel free to share this among your networks.
To view or add a comment, sign in
-
🔍 Simplify your clinical trial search with the help of the MPE Navigator! 💡Unlock information and streamline your search for clinical trials with our platform. You can find trials tailored to your needs, from specific hospitals to disease stages and more. Visit the #MPENavigator to learn more and start your search today: https://lnkd.in/dDRHsv2Z #ClinicalTrials #myeloma #ALamyloidosis
Myeloma and AL Amyloidosis Trial Navigator
navigator.mpeurope.org
To view or add a comment, sign in
-
Incredible results in a challenging study proves #Dermtech can accurately rule out melanoma greater than 99% of the time. Trust II is a follow up study on an already successful trial; which is rarely done. The reason being that the possibility of contradicting your initial positive results is a risk very few companies are willing to take. #Dermtech enrolled 8,000 more patients than Trust I to validate its claims as a first in class melanoma rule out test. The outcome provides concordance to TRUST 1 that the NPV for this test is still greater than 99%
The Trust 2 Study, initiated in 2021, enrolled over 20,000 patients tested with the DMT in a real-world clinical setting.
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT) — Business Wire
stocks.apple.com
To view or add a comment, sign in
-
HER3-DXd shows an intriguing response rate in a highly pretreated population. EGFR-mutated patients who were previously treated with both and oral TKI and platinum-based chemotherapy were adminstered HER3-DXd in this phase II clinical trial. The ORR was 29.8%, median OS was 11.9 months, and median PFS was 5.5 months. The reported rate of ILD was 5.3%, much lower than the reported rate of ILD for HER2-DXd, although this may increase with longer follow-up. We currently do not have many great treatments in EGFR-mutated patients after progression on an oral EGFR TKI, so enrollment in the ongoing phase III trial (HERTHENA-Lung02) is probably the best option for patients who progress. https://lnkd.in/dUryH3tc
To view or add a comment, sign in
-
Databases of clinical trials have not yet been harmonized. Differences in data representations complicate finding a trial that matches your patient's personal and genomic profile. In this video https://lnkd.in/e9zUzw7K, our Head of Clinical Decision Support, Dr. Matthias Kopf, explains the importance of aligning clinical trial eligibility criteria, including biomarkers, to patient needs. MH Guide uses carefully designed criteria and algorithms to match patients to clinical trials, building on a more nuanced assessment of biomarkers used for inclusion, stratification, and/or exclusion to facilitate decisions. Learn more about MH Guide: https://lnkd.in/eq2dv2JV #precisionmedicine #clinicaltrials #biomarkers #cancer #healthcare #pathology #oncology
MH Guide standardizes and matches clinical trial criteria to your patients
https://www.youtube.com/
To view or add a comment, sign in
-
Today at #SITC23 we presented positive preliminary data from our Phase 1/2 #HPK1 clinical trial. Key takeaway: In the dose escalation portion, monotherapy treatment resulted in clinical benefit in 3 patients out of 13 patients with at least 1 post-baseline response assessment as of data cutoff, with complete response in one patient and prolonged stable disease in two patients. We are excited by these preliminary efficacy and safety results, supporting HPK1 as a promising immunotherapy target and continued clinical evaluation of NDI-101150. View our poster for more on the data presented: https://bit.ly/3FI3q4H
To view or add a comment, sign in
-